Overview


According to FutureWise analysis the market for acute respiratory distress syndrome (ards) is expected to register a CAGR of 10.30% from 2023-2031.

Acute Respiratory Distress Syndrome is a medical condition characterized by the rapid onset of respiratory failure, where the lungs cannot provide sufficient oxygen to the body. ARDS occurs due to fluid accumulation in the lungs, leading to difficulty breathing and low oxygen levels in the blood. This condition can be life-threatening and requires immediate medical attention. Various factors, including trauma, sepsis, pneumonia, and inhalation of toxic substances, can cause ARDS. It can also be a complication of other medical conditions, such as heart disease or cancer. The exact cause of ARDS is not fully understood, but it is believed to occur due to an inflammatory response in the lungs. Symptoms of ARDS include shortness of breath, rapid breathing, low oxygen levels, and blue-tinged skin or lips. The diagnosis of ARDS is made based on a combination of clinical presentation, radiological imaging, and laboratory findings. Imaging tests, such as CT scans and chest X-rays, can help identify ARDS's characteristic features, such as diffuse infiltrates in the lungs.

Treatment for ARDS focuses on providing supportive care, such as mechanical ventilation to improve breathing and oxygen therapy to maintain adequate levels of oxygen in the blood. Medications such as antibiotics and corticosteroids may also be used to treat underlying infections and reduce inflammation. In severe cases, extracorporeal membrane oxygenation (ECMO), a type of life support system, may be necessary to provide oxygen to the body. Prevention of ARDS involves identifying and treating underlying conditions that increase the risk of developing the condition, such as sepsis or pneumonia. Measures such as avoiding smoking, improving air quality, and getting vaccinated against certain infections can also help reduce the risk of developing ARDS.

FutureWise Market Research has published a report that provides an insightful analysis of Acute Respiratory Distress Syndrome Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Acute Respiratory Distress Syndrome Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Atersys Inc
  • MondoBIOTECh AG
  • HEALIOS K.K.
  • GlaxoSmithKline Plc
  • Pfizer Inc
  • Teva Pharmaceuticals
  • Altor bioScience
  • Faron Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Acute Respiratory Distress Syndrome Market:

  • In April 2022, A landmark Phase 3 clinical research employing Direct Biologics' investigational EV drug ExoFlow to treat Acute Respiratory Distress Syndrome was given FDA approval.

ARDS can be fatal and requires immediate medical attention. Several factors, including the increasing prevalence of respiratory diseases, technological advancements, and rising healthcare expenditure in diagnostic and treatment options drive the ARDS market. Additionally, the increasing geriatric population is also a major driver for the market, as they are more susceptible to respiratory diseases, including ARDS. The market is also influenced by various initiatives undertaken by governments and non-profit organizations to raise awareness about ARDS and provide better healthcare services. For instance, the World Health Organization (WHO) has launched various programs to prevent and manage ARDS in different countries.

However, the high cost of treatment and the lack of awareness and understanding about ARDS among patients and healthcare professionals are some of the major challenges the ARDS market faces. Additionally, the COVID-19 pandemic has also impacted the market dynamics, with an increasing number of ARDS cases reported due to the virus.

Despite these challenges, the ARDS market is expected to grow in the years to come, driven by the increasing demand for effective treatments and the development of novel therapies. Various pharmaceutical and biotech companies are investing in research and development activities to introduce innovative treatment options for ARDS. Additionally, the increasing adoption of telemedicine and other digital health technologies is expected to improve the delivery of healthcare services for ARDS patients.

By Drug Class

  • Vasoconstrictors
  • Bronchodilators
  • Steroids and Antibiotics
  • Nitric Oxide
  • Sedatives and Paralytics
  • Surfactant
  • Others

By Route of Administration

  • Oral
  • Injection
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. Due to the existence of major market participants, a rise in product approvals, an advanced healthcare system, and a high frequency of acute respiratory distress syndrome, North America led the global market for ARDS. The frequency of ARDS in the United States is reported to vary from 64.2 to 78.9 instances per 100,000 individuals per year, according to research named "Acute Respiratory Distress Syndrome" which was published in the National Library of Medicine in February 2022. Initial evaluations of ARDS cases place 25% in the mild group and 75% in the moderate or severe group. However, one-third of mild cases progress to become moderate or severe conditions. As a result, the rising prevalence of ARDS in North America promotes market expansion throughout the projection period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Acute Respiratory Distress Syndrome (ARDS) Market By Drug Class, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Acute Respiratory Distress Syndrome Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Acute Respiratory Distress Syndrome Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Acute Respiratory Distress Syndrome Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Acute Respiratory Distress Syndrome Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Vasoconstrictors
        2. Bronchodilators
        3. Steroids and Antibiotics
        4. Nitric Oxide
        5. Sedatives and Paralytics
        6. Surfactant
        7. Others

  • 8.   Acute Respiratory Distress Syndrome Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Injection
        3. Inhalation

  • 9.   Acute Respiratory Distress Syndrome Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
        4. Others

  • 10.   North America Acute Respiratory Distress Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Acute Respiratory Distress Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Acute Respiratory Distress Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Acute Respiratory Distress Syndrome Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Atersys Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. MondoBIOTECh AG
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. HEALIOS K.K.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. GlaxoSmithKline Plc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Pfizer Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Teva Pharmaceuticals
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Altor bioScience
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Faron Pharmaceuticals
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients